

World Journal of *Gastroenterology*

World J Gastroenterol 2021 October 7; 27(37): 6161-6347



Contents

Weekly Volume 27 Number 37 October 7, 2021

FRONTIER

- 6161 Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases
Sharma SP, Suk KT, Kim DJ

OPINION REVIEW

- 6180 Surveillance for hepatocellular carcinoma at the community level: Easier said than done
Del Poggio P, Mazzoleni M, Lazzaroni S, D'Alessio A

REVIEW

- 6191 Challenges and opportunities in the application of artificial intelligence in gastroenterology and hepatology
Christou CD, Tsoulfas G

MINIREVIEWS

- 6224 Impact of *Helicobacter pylori* infection on gut microbiota
Iino C, Shimoyama T
- 6231 Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring
Albader F, Golovics PA, Gonczi L, Bessissow T, Afif W, Lakatos PL

ORIGINAL ARTICLE

Basic Study

- 6248 Increased systemic RNA oxidative damage and diagnostic value of RNA oxidative metabolites during *Shigella flexneri*-induced intestinal infection
Nie JJ, Pian YY, Hu JH, Fan GQ, Zeng LT, Ouyang QG, Gao ZX, Liu Z, Wang CC, Liu Q, Cai JP

Retrospective Cohort Study

- 6262 Hepatitis B virus persistent infection-related single nucleotide polymorphisms in HLA regions are associated with viral load in hepatoma families
Hsieh AR, Fann CSJ, Lin HC, Tai J, Hsieh SY, Tai DI

Retrospective Study

- 6277 Recently acquired hepatitis C virus infection among people living with human immunodeficiency virus at a university hospital in Taiwan
Huang MH, Sun HY, Ho SY, Chang SY, Hsieh SM, Sheng WH, Chuang YC, Huang YS, Su LH, Liu WC, Su YC, Hung CC

Observational Study

- 6290** *Helicobacter pylori* in gastric cancer: Features of infection and their correlations with long-term results of treatment
Senchukova MA, Tomchuk O, Shurygina EI

SYSTEMATIC REVIEWS

- 6306** Determination of gluten immunogenic peptides for the management of the treatment adherence of celiac disease: A systematic review
Coto L, Mendia I, Sousa C, Bai JC, Cebolla A

CASE REPORT

- 6322** Pancreatic paraganglioma diagnosed by endoscopic ultrasound-guided fine needle aspiration: A case report and review of literature
Lanke G, Stewart JM, Lee JH
- 6332** Abdominal cocoon in children: A case report and review of literature
Keese D, Schmedding A, Saalabian K, Lakshin G, Fiegel H, Rolle U

LETTER TO THE EDITOR

- 6345** Gastrointestinal symptoms in patients with COVID-19: Is there a relationship with mortality and new variations of SARS-CoV-2?
Ribeiro IB, de Moura DTH, de Moura EGH

ABOUT COVER

Editorial Board Member of *World Journal of Gastroenterology*, Yoichi Matsuo, MD, PhD, Professor, Department of Gastroenterological Surgery, Nagoya City University Graduate School of Medical Sciences, Kawasumi 1, Mizuho-cho, Mizuho-ku, Nagoya 4678601, Japan. nukemat0328@gmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Gastroenterology* (WJG, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING

The WJG is now indexed in Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central, and Scopus. The 2021 edition of Journal Citation Report® cites the 2020 impact factor (IF) for WJG as 5.742; Journal Citation Indicator: 0.79; IF without journal self cites: 5.590; 5-year IF: 5.044; Ranking: 28 among 92 journals in gastroenterology and hepatology; and Quartile category: Q2. The WJG's CiteScore for 2020 is 6.9 and Scopus CiteScore rank 2020: Gastroenterology is 19/136.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Ying-Yi Yuan*, Production Department Director: *Xiang Li*, Editorial Office Director: *Ze-Mao Gong*.

NAME OF JOURNAL

World Journal of Gastroenterology

ISSN

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE

October 1, 1995

FREQUENCY

Weekly

EDITORS-IN-CHIEF

Andrzej S Tarnawski, Subrata Ghosh

EDITORIAL BOARD MEMBERS

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

PUBLICATION DATE

October 7, 2021

COPYRIGHT

© 2021 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Gastrointestinal symptoms in patients with COVID-19: Is there a relationship with mortality and new variations of SARS-CoV-2?

Igor Braga Ribeiro, Diogo Turiani Hourneaux de Moura, Eduardo Guimarães Hourneaux de Moura

ORCID number: Igor Braga Ribeiro 0000-0003-1844-8973; Diogo Turiani Hourneaux de Moura 0000-0002-7446-0355; Eduardo Guimarães Hourneaux de Moura 0000-0003-1215-5731.

Author contributions: Ribeiro IB conceptualized the study and wrote the manuscript; de Moura DTH and de Moura EGH performed the critical final review of manuscript.

Conflict-of-interest statement: There is nothing to disclose.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Invited manuscript

Specialty type: Gastroenterology and hepatology

Igor Braga Ribeiro, Diogo Turiani Hourneaux de Moura, Eduardo Guimarães Hourneaux de Moura, Departamento de Gastroenterologia, Serviço de Endoscopia Gastrointestinal do Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo 05403-010, Brazil

Corresponding author: Igor Braga Ribeiro, MD, Associate Research Scientist, Surgeon, Departamento de Gastroenterologia, Serviço de Endoscopia Gastrointestinal do Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, Av. Dr Enéas de Carvalho Aguiar, 225, 6o andar, bloco 3, São Paulo 05403-010, Brazil. igorbraga1@gmail.com

Abstract

Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although, respiratory symptoms are typical the digestive system is also a susceptible target with gastrointestinal symptoms present even in the absence of respiratory symptoms. The gastrointestinal symptoms of COVID-19 include diarrhea, abdominal pain, anorexia, and nausea among other symptoms. Some questions that remain to be answered include: Do patients with gastrointestinal symptoms have a higher mortality? SARS-CoV-2 variants are already a global reality: Do these variants present with a greater prevalence of gastrointestinal symptoms? Do patients with these symptoms warrant more intensive care unit care?

Key Words: COVID-19; SARS-CoV-2; Gastrointestinal symptoms; Intensive care unit; Variant

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: With the emergence of new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its clinical manifestations, the following questions have arisen: are gastrointestinal symptoms and complications the same as the other variants or are they different? And are these related to severity of the disease? In this letter to the editor, we discuss the relationship between the new SARS-CoV-2 variants with gastrointestinal manifestations and the severity of disease with the new variants.

Citation: Ribeiro IB, de Moura DTH, de Moura EGH. Gastrointestinal symptoms in patients

Country/Territory of origin: Brazil**Peer-review report's scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): D

Grade E (Poor): 0

Received: June 29, 2021**Peer-review started:** June 29, 2021**First decision:** July 13, 2021**Revised:** July 14, 2021**Accepted:** August 25, 2021**Article in press:** August 25, 2021**Published online:** October 7, 2021**P-Reviewer:** Kumar A, Zhang H**S-Editor:** Fan JR**L-Editor:** Filipodia**P-Editor:** Li X

with COVID-19: Is there a relationship with mortality and new variations of SARS-CoV-2? *World J Gastroenterol* 2021; 27(37): 6345-6347

URL: <https://www.wjgnet.com/1007-9327/full/v27/i37/6345.htm>

DOI: <https://dx.doi.org/10.3748/wjg.v27.i37.6345>

TO THE EDITOR

We read with interest the article by Cao *et al*[1] titled "Coronavirus disease 2019 (COVID-19) and its effects on the digestive system."

In 2020, our team conducted a cohort study[2] evaluating 400 patients diagnosed with COVID-19 that, even though it is the largest study in Latin America, unfortunately, was not included in the author's review. In our study, 33.25% of patients reported one or more gastrointestinal symptoms, with diarrhea being the most common, representing approximately 17% of the total. This data corroborates the author's review. It was also found that when these patients had gastrointestinal symptoms, they had a greater tendency to have other concomitant symptoms, especially myalgia and fatigue ($P < 0.05$).

It was also observed that patients with chronic kidney disease ($P < 0.05$), using chronic immunosuppressants, or chronic use of angiotensin receptor blockers or angiotensin-converting enzyme inhibitors had a higher prevalence of gastrointestinal symptoms. Admission to the intensive care unit (ICU), need for mechanical ventilation, length of stay in the ICU, length of hospital stay, need for vasopressor support, laboratory results, and hospital mortality did not differ based on the presence of gastrointestinal symptoms ($P > 0.05$). Regression analyzes showed that immunosuppression [odds ratio (OR): 2.60 (95% confidence interval (CI): 1.20-5.63)], male sex [OR: 1.94 (95%CI: 1.12-3.36)], and older age [OR: 1.04 (95%CI: 1.02-1.06)] were associated with increased mortality.

As described above, our study[2] demonstrated, before the emergence of the new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[3,4], that gastrointestinal symptoms were not associated with a greater need for ICU admission or the severity of the disease in patients in Latin America.

This is a very controversial topic; some studies suggest a less severe clinical evolution in patients with gastrointestinal symptoms[5,6], whereas in the study by Redd *et al*[7], there was no statistical difference.

The study by Leal *et al*[8], evaluating 234 European patients with digestive symptoms, also had a more favorable and non-severe prognosis.

In a review carried out by Wang *et al*[9], it was observed that pancreatic damage or mesenteric ischemia/thrombosis could increase mortality.

In the pediatric population, in the study by de Paula *et al*[10], logistic regression analysis identified that laboratory-confirmed COVID-19 pediatric patients with gastrointestinal symptoms had an increased risk of cardiac abnormalities confirmed by echocardiogram (OR: 6316; 95%CI: 1.717-79043; $P = 0.012$).

We emphasize that in all these studies there was no distinction regarding the variety of SARS-CoV-2 studied.

It is currently known that the high expression of angiotensin-converting enzyme 2 in the lung and the intestinal tract makes the small bowel and colon highly susceptible to SARS-CoV-2 infection, which offers a potential explanation for diarrhea observed in many COVID-19 patients. Since tryptophan absorption requires angiotensin-converting enzyme 2, its deficiency can alter the intestinal microbiota and cause intestinal inflammation[11].

Given the above, we believe a more realistic discussion to be made, and we ask the authors the following: (1) Do patients with gastrointestinal symptoms have more severe disease outcomes or not? (2) Do SARS-CoV-2 variants have a greater gastrointestinal involvement? (3) Do SARS-CoV-2 variants have a relationship between gastrointestinal symptoms and/or disease severity? and (4) Do these patients have a greater need for admission to ICUs?

Finally, we would like to congratulate and thank the authors on the level of shared evidence.

ACKNOWLEDGMENTS

We would like to thank Dr. Sergio A. Sánchez-Luna for reviewing the English translation of this article.

REFERENCES

- 1 **Cao TT**, Zhang GQ, Pellegrini E, Zhao Q, Li J, Luo LJ, Pan HQ. COVID-19 and its effects on the digestive system. *World J Gastroenterol* 2021; **27**: 3502-3515 [PMID: [34239265](#) DOI: [10.3748/wjg.v27.i24.3502](#)]
- 2 **Moura DTH**, Proença IM, McCarty TR, Sagae VMT, Ribeiro IB, Oliveira GHP, Souza GMV, Hirsch BS, Scatimburgo MVCV, Thompson CC, Carrilho FJ, Ceconello I, Moura EGH. Gastrointestinal Manifestations and Associated Health Outcomes of COVID-19: A Brazilian Experience From the Largest South American Public Hospital. *Clinics (Sao Paulo)* 2020; **75**: e2271 [PMID: [33146362](#) DOI: [10.6061/clinics/2020/e2271](#)]
- 3 **SayedAlinaghi S**, Mirzapour P, Dadras O, Pashaei Z, Karimi A, MohsseniPour M, Soleymanzadeh M, Barzegary A, Afsahi AM, Vahedi F, Shamsabadi A, Behnezhad F, Saeidi S, Mehraeen E, Shayesteh Jahanfar. Characterization of SARS-CoV-2 different variants and related morbidity and mortality: a systematic review. *Eur J Med Res* 2021; **26**: 51 [PMID: [34103090](#) DOI: [10.1186/s40001-021-00524-8](#)]
- 4 **Harvey WT**, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, Ludden C, Reeve R, Rambaut A; COVID-19 Genomics UK (COG-UK) Consortium, Peacock SJ, Robertson DL. SARS-CoV-2 variants, spike mutations and immune escape. *Nat Rev Microbiol* 2021; **19**: 409-424 [PMID: [34075212](#) DOI: [10.1038/s41579-021-00573-0](#)]
- 5 **Mao R**, Qiu Y, He JS, Tan JY, Li XH, Liang J, Shen J, Zhu LR, Chen Y, Iacucci M, Ng SC, Ghosh S, Chen MH. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol* 2020; **5**: 667-678 [PMID: [32405603](#) DOI: [10.1016/S2468-1253\(20\)30126-6](#)]
- 6 **Aghemo A**, Piovani D, Parigi TL, Brunetta E, Pugliese N, Vespa E, Omodei PD, Preatoni P, Lleo A, Repici A, Voza A, Cecconi M, Malesci A, Bonovas S, Danese S; Humanitas COVID-19 Task Force. COVID-19 Digestive System Involvement and Clinical Outcomes in a Large Academic Hospital in Milan, Italy. *Clin Gastroenterol Hepatol* 2020; **18**: 2366-2368.e3 [PMID: [32437870](#) DOI: [10.1016/j.cgh.2020.05.011](#)]
- 7 **Redd WD**, Zhou JC, Hathorn KE, McCarty TR, Bazarbashi AN, Thompson CC, Shen L, Chan WW. Prevalence and Characteristics of Gastrointestinal Symptoms in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection in the United States: A Multicenter Cohort Study. *Gastroenterology* 2020; **159**: 765-767.e2 [PMID: [32333911](#) DOI: [10.1053/j.gastro.2020.04.045](#)]
- 8 **Leal T**, Costa E, Arroja B, Gonçalves R, Alves J. Gastrointestinal manifestations of COVID-19: results from a European centre. *Eur J Gastroenterol Hepatol* 2021; **33**: 691-694 [PMID: [33787540](#) DOI: [10.1097/MEG.0000000000002152](#)]
- 9 **Wang MK**, Yue HY, Cai J, Zhai YJ, Peng JH, Hui JF, Hou DY, Li WP, Yang JS. COVID-19 and the digestive system: A comprehensive review. *World J Clin Cases* 2021; **9**: 3796-3813 [PMID: [34141737](#) DOI: [10.12998/wjcc.v9.i16.3796](#)]
- 10 **de Paula CSY**, Palandri GG, Fonseca TS, Vendramini TCA, Farhat SCL, Pereira MFB, Litvinov N, Toma RK, de Sá FVM, Rodrigues KR, Schwartsman C, Forsait S, Sakita NK, Kanunfre KA, Rocha MC, Dos Santos EH, Okay TS, Pinho JRR, de Carvalho WB, Carneiro-Sampaio M, Almeida Silva CA, Marques HHS; Pediatric COVID HC-FMUSP Study Group. Gastrointestinal manifestations are associated with severe pediatric COVID-19: A study in tertiary hospital. *J Infect* 2021; **83**: e22-e25 [PMID: [33940088](#) DOI: [10.1016/j.jinf.2021.04.030](#)]
- 11 **Ma C**, Cong Y, Zhang H. COVID-19 and the Digestive System. *Am J Gastroenterol* 2020; **115**: 1003-1006 [PMID: [32618648](#) DOI: [10.14309/ajg.0000000000000691](#)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

